Core Viewpoint - 基石药业's RET inhibitor, Pralsetinib (普吉华®), has been included in the latest National Medical Insurance Drug List in China, effective January 1, 2026, which is expected to enhance its market penetration and sales growth [1] Group 1: Company Developments - 基石药业's stock rose by 5.57% to HKD 6.07, with a trading volume of HKD 22.7042 million [1] - The company has successfully advanced four innovative drugs to market approval, with three of them having completed clinical trials and registration in China, now included in the national medical insurance list [1] Group 2: Market Expectations - Tianfeng Securities reported in August that the inclusion of Pralsetinib in the insurance list is anticipated to accelerate its market uptake [1] - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] Group 3: Technological Advancements - 基石药业 has developed an innovative internal ADC technology platform, characterized by optimized proprietary linkers to improve tumor-selective payload release [1] - The platform supports multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for the company's future growth [1]
港股异动 | 基石药业-B(02616)涨超5% 普拉替尼获纳入国家医保目录 公司2.0管线矩阵持续扩大